This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Webinar slides: challenging the treatment paradigm for mCRPC with precision medicine in UK practice

On 26 January 2021, an expert panel of Dr Simon Crabb, Dr Deborah Enting and Dr Joaquin Mateo discussed key topics regarding the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) with LYNPARZA (olaparib), including:

  • An update on the licensed approval of LYNPARZA in mCRPC
  • The current unmet need in mCRPC and how LYNPARZA may address this need
  • Key clinical trial data involving patients with BRCA1/2 mutations from the PROfound trial
  • The need for BRCA1/2 genetic testing to identify eligible patients for LYNPARZA treatment
  • Best practice in the management of patients treated with LYNPARZA

More information about LYNPARZA (olaparib) in Prostate Cancer:

LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1

Reference

  1. LYNPARZA (tablets) Summary of Product Characteristics.

Supporting documentation

100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-27140 | Date of Preparation: March 2021